TQ Therapeutics completed the acquisition of Juno Therapeutics GmbH.

TQ Therapeutics, a pharmaceutical company, completed the acquisition of Juno Therapeutics, the German subsidiary of Juno Therapeutics. Financial terms were not disclosed. “This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future. This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients,” Dr. Christian Eckert, TQx CEO.